ESMO 2024 Conference Review focus on Lung Cancer

In this edition:

RATIONALE-315: peri-operative anti-PD-1 + chemotherapy in resectable NSCLC
GALAXIES Lung-201: first-line belrestotug + dostarlimab in PD-L1-high NSCLC
RELATIVITY-104: first-line nivolumab + relatlimab + platinum-doublet chemotherapy for NSCLC
MARIPOSA-2: second interim OS analysis
MARIPOSA-3: acquired resistance to first-line amivantamab + lazertinib vs. osimertinib in EGFR-altered NSCLC
ALKOVE-1: a fourth-generation ALK-inhibitor for ALK-positive solid tumours
Circadian rhythm & immunotherapy response in NSCLC
Perioperative landiolol for prevention of completely resected NSCLC
Respiratory function after neoadjuvant chemotherapy ± immunotherapy for NSCLC
Non-classical EGFR mutations in NSCLC
Low- vs. standard-dose pembrolizumab for metastatic NSCLC
NEOSTAR & CA209-159: 5-year outcomes
BMS-986012 + carboplatin + etoposide + nivolumab in first-line ES-SCLC
ADRIATIC: Durvalumab outcomes by prior concurrent chemoradiotherapy & PCI in LS-SCLC